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The serum substance (Ss)  and sex-linked protein (Slp) molecules are mouse plasma 
proteins  that  exhibit  genetic  variations  controlled  by  the S  region  of the Ho2 gene 
complex  (1).  The  function  of these  proteins  remained  unknown  for  over  a  decade 
until  1973  when  Demant  et  al.  (2)  showed  that  total  hemolytic  complement  levels 
were linked to H-2 and that antisera to Ss markedly decreased the whole complement 
titer.  Subsequently,  considerable  evidence  was  developed  to  demonstrate  antigenic 
(3),  structural  (4-6),  and  functional  (6-10)  homologies  between  murine  Ss  protein 
and  human  C4.  It  is  now  generally  accepted  that  the  Sip-negative  subclass  of Ss 
molecules  is  murine  C4.  However,  Sip-positive  Ss  molecules,  although  structurally 
quite similar to Ss or C4  (5, 6), do not possess hemolytic activity  (6).  During studies 
designed  to  elucidate  the  function  of the  Sip-positive  Ss  molecules,  a  C4  molecule 
with reduced hemolytic efficiency was discovered in the H-2  w7 haplotype. 
Materials and Methods 
The hemolytic assay for murine C4 has been described previously in abstract  form (10)  and 
will be  reported  in  detail  elsewhere. 1 This  sensitive, one-step  hemolytic assay  employs sheep 
erythrocytes  (E)  sensitized with  a  subagglutinating  dilution  (1/400)  of rabbit  IgG antiserum 
(Cordis Laboratories  Inc., Miami, Fla.), C4-deficient guinea pig serum  (C4DGPS)  diluted  1/ 
20, and the test sample. The concentrations of metals (0.015  mM Ca  ++ and  1 mM Mg++), the 
low  ionic  strength  buffer  utilized  (isotonic  dextrose  mixed  with  equal  portions  of isotonic 
veronal-buffered  saline,  /~  =  0.075)  (DVBS),  and  the  duration  (2  h)  and  temperature  of 
incubation  (37°C)  have been  systematically  evaluated  and  found  to  be  similar  to  the  assay 
described  by  Gaither  et  al.  (11)  for the  determination  of human  or guinea  pig C4.  Critical 
differences permitting the measurement of murine C4 were the use of IgG, as opposed to IgM 
or hemolysin,  to sensitize E, and  relatively high  concentrations  of C4DGPS.  Mouse  antisera 
(predominantly  IgG)  raised  against  E  also  served  as  satisfactory  sensitizing  antibody  in  this 
assay system, but provided no advantages over rabbit  IgG. Addition of 1 U  of oxidized or  10 
U  of  unoxidized  human  C2  (Cordis  Laboratories  Inc.)  to  the  assay  increased  the  titers 
approximately  twofold,  presumably  helping  to  overcome a  partial  incompatibility  between 
guinea pig C2 and  mouse C4 (6,  12). 
Murine C2 was measured with an identical assay except for the substitution of C2-deficient 
human  serum for the C4DGPS and an incubation  time of 1 h. 
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Antisera to Ss and Sip were prepared by standard methods that have been recently described 
(3,  5,  13). Goat  antiserum  to  human  factor B  that  cross-reacts with  murine  factor B  was 
purchased from Atlantic Antibodies, Westbrook, Maine  (5).  Rabbit antiserum to mouse C3 
was a gift of Dr. Phillip Hoffsten, Washington University School of Medicine, St. Louis, Mo. 
and also purchased from N. L. Cappel Laboratories, Cochranville, Pa. 
Mice,  obtained  from  our  colony,  were  bled  from  the  retro-orbital  venous  plexus  into 
microfuge tubes using capillary pipettes. Unless noted otherwise, blood was collected in EDTA 
to a  final concentration of 5 raM. Reagents and dilutions were made in DVBS and kept at 
4°C. Although long-term (up to at least 6 mo at -70°C) or short-term (2 h at 4°C) storage of 
mouse plasma (5 mM EDTA)  does not result in the loss of hemolytic activity, for all of the 
experiments in this report, mouse plasmas, after procurement, were maintained at 4°C for no 
longer than  1 h before assay. Serum is an unacceptable test material for the determination of 
murine C4 (10) 1 because of rapid depletion of murine C4 functional activity (even at 4°C). 
For the  anti-Ss and  anti-Sip depletion experiments, Staphylococcus  aureus,  Cowan  I  strain 
(SACI)  (gift of Dr.  B.  Schwartz, Washington University School of Medicine) or protein A- 
Sepharose CL-4B (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) was 
washed  once  in  phosphate-buffered saline, centrifuged  at  1,800  g  for  10  min  at  4°C,  and 
resuspended to a  10% suspension. EDTA mouse plasmas were incubated for  10 rain at 4°C 
with a predetermined quantity ofanti-Ss or anti-Sip (as determined by radial immunodiffusion) 
that was sufficient to bind the amounts of Ss or Sip antigen known to be present in a  given 
strain. The mixture was then transferred to a pellet of SACI (10 volumes of a  10% suspension 
to 1 volume of antiserum) or protein A-Sepharose CL-4B (1 volume of swollen gel per 2 volumes 
of antiserum),  resuspended and  incubated for  10 min  at  4°C.  Plasma was diluted  1:3  with 
DVBS and the samples were centrifuged at  1,800 g for 10 min at 4°C. The supernate was then 
removed and one aliquot diluted as previously indicated for use in the hemolytic assay. Other 
aliquots were stored at -70°C for subsequent determination of Ss and Sip antigenic concentra- 
tions by radial immunodiffusion. Controls, to which the same quantities of SACI or protein A- 
Sepharose CL-4B  but  no antisera were added, were simultaneously evaluated for each  test 
sample. Similar experiments were performed to deplete mouse C3 and factor B. 
Results 
In >50 experiments with 13 different strains (including 9 recombinants) that possess 
the S region of the H-2 k  haplotype  (denoted S k region)  on  three backgrounds  (B10, 
C3H, and A), the hemolytic C4 activity for an S k strain was always <  15% of that for 
48  other  strains  (including  30  independent  and  18  recombinant  haplotypes)  not 
possessing the  S k  region.  The  only exceptions were  strains  with  the  S~  region,  in 
which a  large percentage of the Ss molecules contain the Sip antigenic marker. Data 
for the standard haplotypes on a  B10 background are shown  in Table I. Except for 
the S w7 strain, the C4 hemolytic activity of the non-S  k strains was ~  10 times that of 
B10.K.  B10.WR  (S  w7)  hemolytic titers were  two  to three times those of B10.K  and 
one-third to one-fourth those of the other strains. One possible explanation for these 
data would be that a  large amount  (50-60%)  of the total Ss in this strain consists of 
Sip-positive Ss  molecules  which  have  been  shown  to  lack  classical C4  functional 
activity  (6).  However,  calculation  of the  residual  Ss  (C4)  antigenic concentrations 
after correction for the Sip-positive Ss molecules suggested that the hemolytic titers of 
S w7 mice should still be severalfold higher than those obtained. 
To analyze this observation further, C4 hemolytic activity was measured in selected 
strains after depletion of Ss or Sip molecules (Table II). EDTA plasmas from mice of 
the  standard  haplotypes  on  B10  background  were  incubated  with  anti-Ss  serum 
(which  removes  both  Sip-positive and  Sip-negative  Ss  molecules)  and  cleared  as 
described in  Materials and  Methods.  These  samples contained  no  detectable func- 
tional C4 or antigenic Ss or Sip activity after such  treatment,  but  retained full C2 
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TABLE I 
C4 Titrations  on Male Mice of the Standard Haplotypes  * 
Ss  Sip 
Strain  H-2  C4  Concentra-  Percent of  H or L  + or -  tion~t  Ss 
%  U/ml 
B10  b  H  0.72  -  0  3,380 ±  758 
BI0.D2  d  H  1.00  +  20-30  4,313 ± 846 
B10.M  f  H  1.01  -  0  4,687 ±  1,104 
B10.K  k  L  0.07  -  0  410 ±  79 
B10.Q  q  H  0.81  -  0  4,529 ±  1,434 
B10.S  s  H  0.93  +  5-10  4,085 ±  1,785 
B10.WR  w7  H  1.24  +  50-60  1,158 ± 212 
* These data represent the mean + SEM for 5-27 mice between 6 and 12 wk of age for each strain. Human 
C2 was not added in these assays, although, except for the approximately twofold increase in titers, the 
results were identical in three similar experiments. 
~t Expressed in arbitrary units: 1.0 equals the level in a pool of B10.D2 male mice. Taken from published 
data (2). 
TABLE II 
Effect of Slp Depletion  on C4 Hemolytic  Titers * 
Plasma  Plasma after Sip depletion 
Strain  SACI  SACI +  anti-Sip  C4/Ss§ 
Ss~ (level)  Sip:t: (per-  C4 
cent of Ss) 
Ss (level)  C4  S~ (level)  C4 
%  U/ml  U/ml  U/ml 
B 10.WR  1.97  4. 0.03  50  65  1,921  zk 221  1.47 +  0.03  963 4. 53  0.70 4. 0.04  979 ~  88  1,399 
B10.A  1.16 4- 0.07  20-30  5,116 ±  210  0.88 4. 0.07  4,076 4.  190  0.67 +  0.04  4,123 4. 274  6,154 
BI0.S  1.48  4. 0.31  4-10  6,952 +  274  1.33 :1:0.20  7,011  4. 351  1.41  +  0.40  6,746 -4- 939  4,784 
B 10.M  1.55  4. 0.22  0  6,905 ::1: 549  1.44  4. 0.26  5,247 4. 338  1.34 4. 0.24  5,712 4. 569  4,263 
* These data represent  the mean 4. SEM for three 6  9-wk-old males for each strain. Similar results were obtained with BI0.WR females and 
C3H.WSlp males and females. 
Expressed in arbitrary units:  1.0 =  level in a B10.D2 male ~tandard. The Sip percentage refers to the percent of Ss molecules that possess the 
Sip marker. Values were determined by radial immunodiffusion. 
§These numbers were obtained by dividing (after Sip depletion)  the C4 hemolytic activity by the Ss antigenic level. BI0.WR  females and 
C3H.WSlp males and females, strains with the w7 haplotype at the S region and therefore possessing large quantities of Sip, also had ratios 
between 500 and  1,500. 
Sip-positive  Ss  molecules  were  depleted,  there  was  no  reduction  in  C4  hemolytic 
activity, confirming the  observations  of Ferreira et  al.  (6)  that  the  Sip-positive Ss 
molecules have no detectable C4 activity. Based on the residual level of Ss antigenic 
activity after  Slp  depletion,  the  level of hemolytic activity in  B10.WR  plasma  was 
lower than  expected.  For example, although  the  residual  Ss  antigen  concentrations 
for  B10.WR  and  B10.A  plasmas  after  depletion  (Table  II)  were  almost  identical, 
B10.A  plasma  had  approximately  four  times  as  much  hemolytic  activity.  Further 
evidence in this regard was obtained by comparing hemolytic C4 titers and antigenic 
concentrations  of  Ss  and  Slp  between  S '°7  strains  and  PL/J.  Because  PL/J  has 
approximately the same total Ss and Sip levels as the S w7 strain, it would be expected 
to have equal quantities of C4 yet the hemolytic C4 titers of PL/J mice are severalfold 
higher than those of S w7 strains (Table III). Another strain, FM, also has similar total 
Ss and  Slp levels and  a  hemolytic C4  level comparable to  that  of the  PL/J. These 
data  strongly suggest  that  the C4  molecules from the S w7  B10.WR  and  C3H.WSlp 
strains have a  lower hemolytic efficiency. ATKINSON ET AL.  BRIEF DEFINITIVE REPORT 
TAaLE  III 
Comparison of Hemolytic C4 Titers between BIO. WR and PL/J* 
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Ss:[: (level)  Sip:I: (level)  C4 
U/ml 
B10.WR (6)  1.96 + 0.16  4.32 ± 0.38  1,805 ± 257 
PL/J (5)  1.93 + 0.07  4.69 ± 0.17  6,161 ± 878 
* These data represent the mean  ±  SEM for 6- to 12-wk-old males. These samples 
were analyzed in parallel. 
Expressed in arbitrary units relative to a standard reference serum. 
TABLE IV 
Effect of Mixing w 7 and k Haplotype Plasmas* 
Haplotype (percentage of each in 
test sample)  Hemolytic U/sample 
100  0  676  -- 
75  25  830  789 
50  50  947  902 
25  72  1,130  1,015 
0  100  1,128  -- 
* This experiment is representative of four similar  experiments in which, before 
C4 functional assay, plasmas from BI0.WR mice were mixed in the above 
proportions with B10.M(f), BI0.A(d), and BI0.HTT(k)  plasmas. The data 
for the k haplotype are shown because low C4 titers of this haplotype provide 
the optimal opportunity to observe inhibition by S w7 plasma. 
The  possibilities that  these  results  could  be  accounted  for  by  inhibitors  in  S w7 
plasma,  by  increased  lability  of  the  S w7  C4  molecule,  or  by  the  Sip  molecules 
functioning as an inefficient or false C4 were evaluated. The last consideration seems 
unlikely because  Sip-positive molecules had  been  depleted  from  the  plasma at  the 
time  of the  C4  functional  assay  in  some  of these  experiments  (Table  II),  because 
PL/J  mice have Sip levels as high as B 10.WR but possess the expected C4 hemolytic 
activity (Table III), and because of the data of others (6) demonstrating that C 1F does 
not cleave the a-chain of Sip-positive molecules. To evaluate the first hypothesis, four 
experiments were performed in which EDTA  plasmas from several different strains, 
with  S  regions  from  the d, f,  and  k haplotypes,  were  mixed  in  varying proportions 
with plasmas from mice of the w7 haplotype (Table IV). In each case, the resultant 
hemolytic titers were equal to the calculated sum of the contributions of each strain 
determined separately. To examine the second possibility, EDTA plasma and serum 
samples from S w7 strains were compared to S k or S d strains with regard to the lability 
of the C4 hemolytic activity. There was a  progressive loss of C4 hemolytic activity in 
sera maintained at  4,  22,  or 37°C  and  the rate in S w7 strains was similar to that  in 
four other standard strains (B 10.M, B 10.S, B 10.D2, and B 10.P). C4 activity in EDTA 
plasmas remained unchanged  in both S w7 and the standard haplotypes for up to 90 
min at 4, 22, or 37°C. Taken together, these data suggest that the reduced functional 
efficiency is not a result of the presence of an inhibitor or of the altered stability of the 
C4 molecule. 
Discussion 
In a  previous report  (5), we demonstrated that  plasma C4 molecules from  strains 
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possessing the S wv region have a  slightly smaller molecular weight  than  plasma C4 
molecules from all other strains tested. These data were obtained by immunoprecip- 
itation of the C4 molecules and characterization of the a-, B-, and -t-chains by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. These analyses revealed that  the 
a-chain of the S w7 haplotype has an apparent 93,000  mol wt, whereas the a-chains 
from  other  inbred  strains  examined  had  apparent  95,000  mol  wt  (5).  Molecular 
weight  differences between S wv and other haplotypes were also documented  for C4 
molecules produced by macrophages in short-term, in vitro cultures. These differences 
suggest that the S w7 haplotype molecule is synthesized at a different molecular weight, 
is  differentially  susceptible  to  an  immediate  postsynthetic  proteolytic  degradation 
step, or is differently glycosylated. In any case, a primary structural difference in the 
S w7 C4 a-chain versus the C4 a-chains of other haplotypes is indicated. 
In  this  study,  this  C4  product  of the  S w7  haplotype has  also  been  shown  to  be 
functionally inefficient. For a  given quantity of antigenic C4, the S w7 haplotype C4 
molecules produce one-third to one-fourth as much lysis as C4 molecules from other 
strains. Reduced stability of this S w7 C4 molecule in plasma or serum or the possibility 
of inhibitors in S wv plasma were shown to be unlikely explanations. Moreover, the C4 
molecule from S wv mice was at least as stable as the C4 molecules derived from mice 
of other haplotypes. In view of the previously described molecular weight differences, 
it seems likely that the structural change in the a-chain of S ~7 C4 molecules makes it 
hemolytically less efficient in a  standard C4 hemolytic assay. Further studies will be 
necessary  to  determine  whether  the  reason  for this  observation  relates  to  reduced 
activation  by  C lg  or  inefficient  formation  and/or  function  of  the  C3  and  C5 
convertases. 
Although there are examples in certain enzyme systems and in hemoglobins where 
amino acid substitution(s)  or altered peptide chain lengths have important effects on 
the specific function of the molecule, this is the first report of a complement molecule 
partially  deficient  in  hemolytic  activity.  Allotypes  of C3  and  factor  B  have  been 
carefully evaluated for functional activity and these variants have been demonstrated 
to  possess  similar  hemolytic  efficiency  (14,  15).  There  is  one  report  suggesting 
differences in opsonic activity among C3 allotypes (16).  In the uncommon variant of 
hereditary  angioedema,  normal  or  elevated  concentrations  of a  nonfunctional  C1 
esterase inhibitor molecule are present (16,  17) and this molecule does not inhibit the 
ability of C lg to split its natural substrates. One difference between these previously 
described  variations in  the complement system and  that  of the S ~7 C4  molecule is 
that  the  former presumably represent  single  amino  acid  substitutions,  whereas  the 
latter is an apparent difference of ~2,000 daltons. The availability of methodologies 
that permit a careful dissection of structural (5) and functional (6,  10; and this paper) 
differences  in  the  C4  and  Sip  molecules  and  their  genetically  controlled  variants 
should  make  it  possible  to  ask additional  important  questions  with  regard  to  the 
immunogenetics of these proteins. 
Summary 
C4 functional activity and antigenic levels were determined in H-2-congenic mouse 
strains.  In strains with  the  H-2 w7 haplotype,  the C4  hemolytic activity per unit  of 
residual  Ss  antigenic  activity,  after  depletion  of  the  nonfunctional  Sip-positive 
molecules was 25-33% that found with other H-2 haplotypes. This reduced hemolytic 
efficiency was not the result of either a  more labile C4 molecule or of the presence of ATKINSON ET  AL.  BRIEF DEFINITIVE REPORT  497 
inhibitors.  Moreover,  other strains  with  comparable  antigenic concentrations  of Ss 
((:14) and Slp had  three- to fourfold higher levels of C4 hemolytic activity. Based on 
these data and previously reported structural differences between C4 molecules from 
the  9-2 w7  haplotype  compared  with  other  standard  H-2  haplotypes,  the  reduced 
hemolytic  efficiency  of  this  molecule  is  probably  secondary  to  alterations  in  the 
structure of its a-chain. 
Received  for publication 15 October 1979. 
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